Brief: Monte Rosa Says Year-End Cash, Cash Equivalents To Provide Runway Into Late 2024
March 29 (Reuters) - Monte Rosa Therapeutics Inc GLUE.O :
* MONTE ROSA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL
YEAR
2021 FINANCIAL RESULTS AND BUSINESS UPDATES
* MONTE ROSA THERAPEUTICS INC - YEAR-END CASH AND CASH
EQUIVALENTS
EXPECTED TO PROVIDE RUNWAY INTO LATE 2024
Source text for Eikon: ID:nGNX3rhR8w
Further company coverage: GLUE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Monte Rosa Therapeutics
See all newsBrief: Monte Rosa Therapeutics Announces Positive Results For Mrt-8102 In Gforce-1 Phase 1 Study Showing Normalization Of Key Pathogenic Drivers Of Ascvd In Subjects With Elevated Cvd Risk
Brief: Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Monte Rosa Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Monte Rosa Therapeutics Q2 revenue drops, net loss widens on higher R&D
Brief: Monte Rosa Therapeutics Q2 Collaboration Revenue USD 8.968 Million